British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy BH1VA

HIV Medicine

Volumn 1, Issue 2, 2000, Pages 76-101

  Pozniak, Anton ^a   Gazzard, Brian ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33746495516     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2000.00013.x     Document Type: Article

References (131)

1. Delfraissy JF, et al. Prise en charge thérapeutique des personnes infectées par le V1H. recommandations du groupe d'experts. France, Flammarion, 1999.
2. Smith D, WhittakerB, Crowe S, et al. Antiretroviral therapy for HIV infection: principles of use (standard of care guidelines). HIV/AIDS Clinical trials and treatments advisory committee booklet (October), 1997.
3. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society-USA Panel. JAMA 2000; 283: 381-390.
4. Centers for Disease Control and Prevention. Report of the NIH Panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMVfR 1998; 47: 1-91.
5. Gazzard B, Moyle G, on behalf of the BHIVA Guidelines Writing Committee. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998; 352: 314-316.
6. Hurwitz B. Legal and political considerations of clinical practice guidelines. BMJ 1999; 318: 661-664.
7. Pozniak A. Surrogacy in HIV-1 clinical trials. Lancet 1998; 351: 536-537.
8. Fleming TR, Demets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125:605-613.
9. De Gruttola V, Fleming T, Lin DY, Coombs R. Perspective: validating surrogate markers - are we being naive? JInfect Dis 1997;175:237-246.
10. Babiker A, for the Delta Co-ordinating Committee and Virology Group. Can HIV-1 RNA viral load be used as a surrogate for clinical endpoints in HIV disease? 6th European Conference on Clinical Aspects and Treatment of HIV Infection, Hamburg, Germany, 1997 (abstract 103).
11. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-954.
12. 10 reduction in clinical trials. AIDS 1998; 12:536 (abstract P77).
13. Raboud JM, Montaner JSG, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998; 12: 1619-1624.
14. ZhuT, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261: 1179-1181.
15. IB Zhang LQ, Mackenzie P, Cleland A, et al. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 1993;67:3345-3356.
16. Markowitz M, Vesanen M, Tenner-Racz K, et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type-1 infection on viral replication and antiviral immune responses. J Infect Dis 1999; 179: 527-537.
17. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. NEngl JMed 1999; 340: 1605-1613.
18. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-4655.
19. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68: 6103-6110.
20. + T cell responses associated with control of viremia [see comments]. Science 1997; 278: 1447-1450.
21. Walker BD, Rosenberg ES, Hay CM, Basgoz N, Yang 00. Immune control of HIV-1 replication. AdvExpMed Biol 1998; 452: 159-167.
22. Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999; 340, 1683-1684.
23. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291-1295.
24. Finzi D,Hermankova M,Pierson T, et al.Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295-1300.
25. Chun T-W, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387: 183-187.
26. Ho DD. Toward HFV eradication or remission: the tasks ahead. Science 1998; 280: 1866-1867.
27. Pontesilli O, Kerkhof-Garde S, Notermans DW, et al. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis 1999; 180:76-86.
28. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type l (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med 1990; 112: 727-737.
29. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871-881.
30. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271: 1582-1586.
31. Yu G, Clendennin NJ, Quart B, eraJ. Viral load levels during treatment with VIRACEPT combination treatment as predictor of response and guidance for treatment choice strategy. 12th World AIDS Conference, Geneva, 1998 (abstract 12300).
32. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. NEnglJMed 1997; 337: 734-739.
33. Green S, Para MF, Daly PW, etal Interim analysis of plasma viral burden reductions and CD4 increases in HIV-1 infected patients with Rescriptor (DLV) + Retrovir (ZDV) + Epivir (3TC). 12th World AIDS Conference, Geneva, 1998 (abstract 129/ 12219).
34. Fischl M, Greenberg S, Clumeck N, et al. Safety and activity of abacavir (1592, ABC) with 3TC/ZDV in antiretroviral naive subjects. 12th World AIDS Conference, Geneva, 1998 (abstract 127/12230).
35. Gisolf EH, de Wolf F, van Wanzeele F, et al.Treatment of ritonavir (RTV)/saquinavir (SQV) versus RTV/SQV/stavudine (d4T) (the Prometheus study): preliminary results. 12th World AIDS Conference, Geneva, 1998 (abstract 12274).
36. Tashima K, Staszewski S, Stryker R, et al.A phase III, multicenter, randomized, open-label study to comapre the antiretroviral activity and tolerability of efavirenz + indinavir, versus EFV + zidovudine + lamivudine, versus IDV + ZDV + 3TC at 48 weeks. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999 (abstract LB-16).
37. Farzadegan H, Hoover DR, Astemborski J, et al.Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998; 352: 1510-1514.
38. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologie and immunologie markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200-500, CD4 cells per cubic millimeter. NEnglJMed 1996; 335:1091-1098.
39. Bush CE, Donovan RM, Markowitz N, et al.Gender is not a factor in serum human immunodeficiency virus type 1 RNA levels in patients with viremia. J Clin Microbiol 1996; 34:970972.
40. Moore RD, Cheever L, Keruly JC, Chaisson RE. Lack of sex difference in CD4 to HIV-1 RNA viral load ratio. Lancet 1999; 353:463-464.
41. + lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review [see comments]. J Infect Dis 1992; 165: 352-363.
42. + T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-116.
43. Brun-Vezinet F, et al.Virologie failure, resistance and plasma drug measurements in an induction maintenance therapy trial (ANRS 072 Trilege). International Conference on the Discovery and Clinical Development of Antiretroviral Therapies, St Thomas, US Virgin Islands, 1998 (abstract 15).
44. Paterson D, Swindells S, Mohr J, et al.How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMSCaps. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999 (abstract 92).
45. Demasi R, Toison J, Pham S, et al.Self-reported adherence to HAART and correlation with HIV RNA. initial results with the Patient Medication Adherence Questionnaire. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999 (abstract 94).
46. Woodward J, Wareham PS, Grohskopf L, Madigan D, Hooton TM. Protease inhibitor adherence and HIV-1 RNA response. 12th World AIDS Conference, Geneva, 1998 (abstract 60363).
47. Ferrando SJ, Wall TL, Batki SL, Sorensen JL. Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. Am J Drug Alcohol Abuse 1996; 22: 475-487.
48. Broers B, Morabia A, Hirschel B. A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med 1994; 154: 1121-1127.
49. Miller L, Liu H, BeckK, eraJ. Providers' estimates of adherence overestimate reports from Medication Event Monitoring System (MEMS) for patients on protease inhibitors (Pis). 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999 (abstract 97).
50. Anderson W, et al.Taking Heart? The impact of combination therapy on the lives of people with HIV (Phase 2). London, Sigma Research, 1999.
51. Arabe J, Rubini NPM, Rodrigues ACA, et al.Factors which influence adherence to the use of protease inhibitors. 12th World AIDS Conference, Geneva, 1998 (abstract 32404).
52. Bachiller P, Arrando FR, Liceaga G, et al.Adherence to antiretroviral therapy in HIV-infected patients. 12th World AIDS Conference, Geneva, 1998 (abstract 32392).
53. Gifford AL, Shively MJ, Bormann JE, et al. Self-reported adherence to combination antiretroviral medication (ARV) regimens in a community-based sample of HIV-infected adults. 12th World AIDS Conference, Geneva, 1998 (abstract 32338).
54. Lorenzen T, Stoehr A, Weitner L, et al.Compliance with antiretroviral multidrug therapy in HIV-infected patients and reasons for non-compliance. 12th World AIDS Conference, Geneva, 1998 (abstract 32371).
55. Nakashima AK, Jones JL, Burgess DA, Ward JW. Adherence to currently prescribed antiretroviral therapies: results from a multisite interview project. 12th World AIDS Conference, Geneva, 1998 (abstract 32326).
56. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993; 269: 729-730.
57. Palella FJ, Delaney KM, Moorman AC, et al.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N EnglJ Med 1998; 338: 853-860.
58. Hammer SM, Squires KM, Hughes MD, et al.A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N EnglJ Med 1997; 337: 725-733.
59. Cameron DW, Heath-Chiozzi M, Danner S, et al.Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998; 351: 543-549.
60. Haubrich R, Lalezari J, Follansbee SE, et al.Improved survival and reduced clinical progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine. Antiviral Tlier 1998; 3:33-42.
61. Kirk O, Katzenstein TL, Gerstoft J, et al.Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. AIDS 1999; 13:F9F16.
62. Moyle G, on behalf of the Spice Study team. Study of protease inhibitor combination in Europe (Spice) ; saquinavir soft gelatin capsule (SQV-SGC) plus nelfmavir (NFV) in HFV-infected individuals. 12th World AIDS Conference, Geneva, 1998 (abstract 12222).
63. D'Aquila RT, Hughes MD, Johnson VA, étal Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol, 241 Investigators. Ann Intern Med 1996; 124:1019-1030.
64. Moyle GJ, Baldwin C, Dent N, eraJ. Management of protease inhibitor (PI) -associated lipodystrophy by substitution with efavirenz in virologically controlled HIV-infected persons. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999 (abstract 2064).
65. Montaner JSG.ReissP, Cooper D, era!. A randomized, doubleblind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS Trial. JAMA 1998; 279: 930-937.
66. Murphy RL, Katlama C, Johnson V, et al. The Atlantic Study: a randomized, open-label trial comparing two protease inhibitor (PJ)-sparing antiretroviral strategies versus a standard Picontaining regimen, 48 week data. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999 (abstract LB-22).
67. Kaspar R. Prednisone during the induction phase of nevirapine therapy appears to reduce the incidence of nevirapineassociated rash. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 1998 (abstract 1-64).
68. Hawkins D, Wood R, Horban A, et al.Final 54-week analysis of a study comparing the safety and antiretroviral activity of dual nucleoside analogues plus placebo versus dual nucleoside analogues plus delavirdine (DLV) in an advanced, treatmentnaive HIV-infected population. 7th European Conference on Clinical Aspects and Treatment of HIV Infection, Lisbon, 1999 (abstract 550).
69. Hawkins D, Wood R, Horban A, et al.Final 54-week analysis of a study comparing the safety and antiretroviral activity of dual nucleoside analogues plus placebo versus dual nucleoside analogues plus delavirdine (DLV) in an advanced, nucleoside analogue-experienced HIV-infected population. 7th European Conference on Clinical Aspects and Treatment of HIV Infection, Lisbon, 1999 (abstract 552).
70. Larder BA. 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992; 36: 2664-2669.
71. Kaufmann D, Pantaleo G, Sudre P, Telenti A, for the Swiss HIV Cohort Study. CD4-cell counts in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998; 351: 723-724.
72. Caesar Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudinecontaining regimens for patients with HIV-1 infection: the CAESAR trial. lancet 1997; 349: 1413-1421.
73. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269: 696-699.
74. Staszewski S, Katlama C, HerrerT, et al.Long-term, 72 week experience with a triple reverse transcriptase nucleoside therapy regimen containing abacavir (1592, ABC): a follow-up of protocol CNA2002. AIDS 1998; 12: S34 (abstract 69).
75. Staszewski S, Keiser F, Gathe J, et al Comparison of antiviral response with abacavir/combivir to indinavir/combivir in therapy-naive adults at 48 weeks (CNA3005). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999 (abstract 505).
76. Havlir DV, Friedland G, Pollard R, et al. Combination zidovudine and stavudine therapy versus other nucleosides: report of two randomized trials (ACTG 290 and 298). 5th Conference on retroviruses and Opportunistic Infections, Chicago, 1998 (abstract 2).
77. Brinkman K, ter Hofstede HJ, Burger DM, etal Adverse effects of reverse transcriptase inhibitors: mitochondria! toxicity as common pathway [editorial]. AfDS 1998; 12: 1735-1744.
78. Fouty B, Frerman F, Rêves R. Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet 1998; 352: 291-292.
79. Lori F, Malykh A, Cara A, et al.Hydroxyurea as an inhibitor of human immunodeficiency virus Type-1 replication. Science 1994;266:801-805.
80. De Boer RJ, Boucher CAB, Perelson AS. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. AIDS 1998; 12: 1567-1570.
81. De Antoni A, Foli A, Lisziewicz J, Lori F. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J Infect Dis 1997; 176: 899-903.
82. Rossero R, Mckinsey D, Green S, et al.Open label combination therapy with stavudine, didanosine and hydroxyurea in nucleoside experienced HIV-1 infected patients. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, 1998 (abstract 653).
83. Margolis D, Heredia A, Gaywee J, et al.Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. JAcquirImmune Dec Syndr 1999; 21: 362-370.
84. Petersen A, Antunes F, Arasteh KN, et al.A comparison of the long-term antiviral efficacy of bid and tid dosing of nelfmavir in combination with stavudine (d4T) and lamivudine (3TC) beyond 48 weeks. Seventh European Conference on Clinical Aspects and Treatment ofHIV-Infection, Lisbon, October 1999 (abstract 205).
85. Barry MG, Merry C, Lloyd J, ef al. Variability in trough plasma saquinavir concentrations in HIV patients - a case for therapeutic drug monitoring [letter]. BrJClin Pharmacol 1998; 45: 501-502.
86. Back D, Eagling V, Profit L. Saquinavir absorption: role of Pglycoprotein. AIDS 1998; 12 (abstract P53).
87. Fletcher CV, Kakuda TN, Anderson PL, etal Viral dynamics of concentration-targeted (C) vs. standard-dose (S) therapy with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1999 (abstract 322).
88. Havlir DV, Marschener 1C, Hirsch MS, et al.Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998; 339: 1261-1268.
89. Ruiz L, van Lunzen J, Amo A, et al.Protease inhibitorcontaining regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS 1999; 13:Fl-F8.
90. Taylor S, Back DJ, Workman J, et al.Poor penetration of the male genital tract by HIV-1 protease inhibitors. AIDS 1999; 13: 859-860.
91. Danner SA, Carr A, Leonard JM, étal. A short-terra study of the safety, pharmacoklnetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N EnglJMed 1995; 333: 1528-1533.
92. Di Perri G, Del Bravo P, Concia E. HIV-protease inhibitors. NEngUMed 1998; 339: 773-774.
93. Nelson MR, Moyle G, Newell A. The incidence of hyperlipidaemia with protease inhibitors (PI). 38th Interscience Conference in Antimicrobial Agents and Chemotherapy, San Diego, 1998.
94. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 352: 1881-1883.
95. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
96. Henry K, Melroe H, Huebsch J, eraJ. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351:1328.
97. Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller FV. Lipodystrophy in patients naive to HIV protease inhibitors. A/DS1999; 13:735-737.
98. Dong K, Flynn MM, Dickinson BP, etal Changes in body habitus in HFV+ women after initiation of protease inhibitor therapy. 12th World AIDS Conference, Geneva, 1998 (abstract 12373).
99. Lo J, Mulligan K, Tai V, Algren H, Schambelen M. 'Buffalo hump' in men with HIV-1 infection. lancet 1998; 351: 867870.
100. Veny A, Bonjoch A, Romeu J, eraJ. Cumulative risk for developing protease inhibitor-associated lipodystrophy (PIAL) in HlV-infected patients. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 1998 (abstract 1-92).
101. Miller K, Jones E, Yanovski J, et al.Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351:871-875.
102. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviraltherapy-related lipodystrophy. lancet 1999; 354: 1112-1115.
103. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor (PI) therapy. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999 (abstract 672).
104. Torres R, linger K. The effect of recombinant human growth hormone on protease-inhibitor-associated fat maldistribution. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999 (abstract 675).
105. Ruiz L, Bonjoch A, Paredes R, et al. A multi-center, randomized, open-label comparative trial of the clinical benefit of switching the protease inhibitor by nevirapine in HAART-experienced patients suffering lipodystrophy. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999 (abstract LB-14).
106. Yee TT, Amrolia PJ, Lee CA, et al Protease inhibitors and unusual bleeding in haemophiliacs. Haemophilia 1997; 3:219-221.
107. Wilde JT, Lee CA, Collins P, et al.Increased bleeding associated with PI therapy in HIV-positive patients with bleeding disorders. BrJHaematol 1999; 107: 556-559.
108. Pilcher CD, Miller WC, Beatty ZA, Eron JJ. Detectable HIV-1 RNA at levels below quantifiable limits by amplicor HIV-1 monitor is associated with virologie relapse on antiretroviral therapy. AIDS 1999; 13: 1337-1342.
109. Gulick RM, Mellors JW, Havlir D, eraJ. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine and lamivudine for HIV-1 infection. JAMA 1998; 280:35-41.
110. Goebel F, the Avanti Study Group. Avanti 2. A randomised, double-blind, comparative trial to evaluate combination antiretroviral regimens for the treatment of HIV-1 infection: AZT/3TC vs. AZT/3TC/Indinavir in antiretroviral naive patients. 6th European Conference on Clinical Aspects and Treatment of HIV Infection, Hamburg, 1997 (abstract 211).
111. Riddler S, Kahn J, Hicks C, et al. Durable anti-HIV-1 activity (72 weeks) and tolerability for efavirenz (DMP 266) in combination with indinavir (IDV) [DMP 266-003, Cohort IV]. 12th World AIDS Conference, Geneva, 1998 (abstract 12359).
112. Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologie response to salvage therapy. Swiss HIV Cohort Study. AIDS 1999; 13: F17-F21.
113. Youle M, Mocroft A, Johnson M, et al. Surrogate marker responses to multidrug combination hydroxyurea, efavirenz, double protease inhibitors and analogues in protease inhibitor failures. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999 (abstract 400).
114. Decks SG, Hecht FM, Swanson M, eraJ. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13:F35-F43.
115. Tebas P, Patick AK, Kane EM, et al. Virologie responses to a ritonavir - saquinavir-containing regimen in patients who had previously failed nelfmavir. Aids 1999; 13: F23-F28.
116. Eron J, Falloon J, Masur H, étal. Activity of combination abacavir/amprenavir/efavirenz therapy in HIV-1 infected subjects failing their current protease inhibitor containing regimen 1998; 12: S13 (abstract OP52).
117. Workman C, Müssen R, Sullivan J. Salvage therapy using six drugs in heavily pretreated patients. 5th Conference on Retrovimses and Opportunistic Infections, Chicago, 1998 (abstract 426).
118. Garcia F, Plana M, Vidai C, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. Aids 1999; 13: F79-F86.
119. Ledergerber B, Egger M, Opravil M, eraJ. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353: 863-868.
120. Decks SG, Parkin N, Petropoulos CJ, ftal. Correlation of baseline phenotypic drug susceptibility with 16 week virologie response in a pilot combination therapy study in HIV-infected patients who failed indinavir therapy. Antiviral Tiier 1998; 3: 36 (abstract 53).
121. Patick A, Zhang M, Hertogs K, et al Correlation of virological response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfmavir in the US expanded access program. Antiviral Ther 1998; 3: 39 (abstract 57).
122. Harrigan PR, Montaner JS, Hogg RS, et al Baseline resistance profile predicts response to ritonavir/saquinavir therapy in a community setting. Antiviral Ttier 1998; 3:38 (abstract 55).
123. Zolopa AR, Shafer RW, Warford A, et al Predictors of antiviral response to saquinavir/ritonavir therapy in a clinical cohort who have failed prior protease inhibitors: a comparison of clinical characteristics, antiretroviral drug history and HIV genotype. Antiviral Ther 1998; 3: 37 (abstract 54).
124. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Merigan TC, and the CPCRA 046 Study Team. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999 (abstract LB8).
125. Durant J, Clevenbergh P, Halfen P, eraJ. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353: 2195-2199.
126. Stuyver L, Wyseur A, Rombout A, et al Line probe assay for rapid detection of drug-selected mutations in the Human Immunodeficiency Virus Type 1 reverse transcriptase gene. Antimicrob Agents Chemother 1997; 41: 284-291.
127. Arnold C, Barlow KL, Kaye S, etal HIV type 1 sequence subtype G transmission from mother to infant: failure of variant sequence species to amplify in the Roche AmpIicorTest. AIDS Res Hum Retroviruses 1995; 11:999-1001.
128. Perrin L. Transmission of drug-resistant HIV. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999 (abstract S35).
129. Little S, Daar E, Keiser P, etal The spectrum and frequency of reduced antiretroviral drug susceptibility with primary HIV infection in the United States. 6th Conference on Retroviruses and Opportunistic Injections, Chicago, 1999 (abstract LB-10).
130. Taylor GP, Lyall EGH, Mercey D, et al British HIV Association guidelines for prescribing antiretroviral therapy in pregnancy 1998. SexTransm Inf 1999; 75: 90-97.
131. Expert Advisory Group on AIDS. Guidelines on Post-exposure Prophylaxis for Health Care Workers Occupationally Exposed to HIV. London, Department of Health, 1997.